diff --git a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md
index 4f3607edb..e6021e9b0 100644
--- a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md
+++ b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md
@@ -27,6 +27,17 @@ related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-
 
 Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% comparison cohort (18-20 percentage point improvement). Persistent members achieved 18.4% average weight loss at 12 months; overall cohort 16.3% weight loss, representing 44% better outcomes than semaglutide real-world evidence. This quantifies the behavioral companion program value proposition with specific persistence and outcome data.
 
+
+### Auto-enrichment (near-duplicate conversion, similarity=1.00)
+*Source: PR #10406 — "digital behavioral support improves glp1 persistence 20 percentage points through coaching and monitoring"*
+*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
+
+## Supporting Evidence
+
+**Source:** Omada Health FY2025 earnings report, March 5, 2026
+
+Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% comparison cohort, representing 18-20 percentage point improvement. Persistent members achieved 18.4% average weight loss at 12 months; overall cohort 16.3% (44% better than semaglutide real-world evidence). This confirms behavioral support creates measurable persistence and outcome improvements.
+
 ---
 
 # Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring